Salute e Benessere
Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer to advance patient-centric innovation in clinical trial design and market access
's innovative approach, driven by its Founder , aims to reduce trial sample sizes and accelerate patient access to new treatments. One2Treat software helps incorporate multiple clinical outcomes that matter to the patient as early as the study design through robust statistical methodologies. Dr. will be a key driver in this endeavor.
Dr. , Prof. of Medical Oncology, brings over 30 years of clinical development experience in both academia and industry, holding positions including Head of Medical Oncology at Paris University, General Director of the Comprehensive Cancer Center of Alsace Region, and several leadership roles in the pharmaceutical industry, including Vice President, Head of Global Oncology and Infectious Diseases at AstraZeneca, Senior Vice President, Medical Head Major Markets at Bristol Myers Squibb and General Manager at Boehringer-Ingelheim Belgium.
" 's extensive medical experience will address one of the most strategic challenges in the biopharma industry today: incorporating multiple patient-relevant outcomes into a single holistic treatment assessment," said , CEO of . "In today's clinical studies, focusing on one or two primary endpoints often leads to underutilization of valuable data and fails to capture the holistic impact of treatments on patients. 's deep industry knowledge will ensure that our innovative solutions bring clinically meaningful transformations in the way we design clinical trials."
Dr. adds: "There is a huge opportunity to involve patients, sponsors, regulatory agencies, and payers early in the clinical trial design process. By aligning on their specific needs and prespecifying the primary endpoint of the registration study, we can run more efficient trials and bring new treatments to market faster. This approach will ensure that clinical trials are more reflective of what truly matters to patients, including quality of life for instance."
, Founder of , highlights the need for a more patient-centric approach in clinical research: "I am delighted that , with whom I have had a long and very fruitful collaboration, joins today. His medical expertise will speed up the implementation of this multi-dimensional approach, ensuring our message resonates with medical leaders."
Dr. concludes: " 's innovative approach also facilitates a more transparent and efficient transition from drug development to market access. Using a rigorous, quantitative method to analyze overall treatment effects allows us to connect clinical research and health technology (HTA) assessment seamlessly, providing a comprehensive benefit-risk assessment based on what matters most to patients."
View original content: https://www.prnewswire.co.uk/news-releases/pascal-piedbois-md-phd-joins-one2treat-as-chief-medical-officer-to-advance-patient-centric-innovation-in-clinical-trial-design-and-market-access-302192054.html